Search

ObjectivesTo assess deviations in longitudinally measured cytokines with preterm birth (PTB).MethodsProspective longitudinal study targeting 80 subjects. Phlebotomy specimens for broad panel of cytokine analysis were obtained at three time (T) intervals: first trimester (T1: 8-14 weeks' gestation), second trimester (T2: 18-22 weeks' gestation), and third trimester (T3: 28-32 weeks' gestation). Important demographics and outcomes were tracked. Data were stratified and the target groups were analyzed as follows: "Uncomplicated" (delivered ≥37 weeks) or "Preterm Birth" (

Objective: To compare self-reported pre-pregnancy weight & delivery weight with documented pre-pregnancy & delivery weight and determine whether there are differences compared with the Institute of Medicine's (IOM) guidelines. Methods: This is a retrospective analysis of 234 women. Inclusion criteria included documented height, self-reported pre-pregnancy weight, self-reported delivery weight, documented pre-pregnancy weight ± 12 weeks from last menstrual period, and documented delivery weight ± 2 weeks from delivery. We determined the difference between self-reported pre-pregnancy weight vs. documented pre-pregnancy weight and self-reported delivery weight vs. documented delivery weight. Using documented pre-pregnancy weight and documented delivery weight, we calculated gestational weight gain (GWG) relative to IOM criteria. Results: Self-reported pre-pregnancy weight was 2.94 kg less than documented pre-pregnancy weight ( p < 0.0001). Self-reported BMI was 1.11 mg/kg2 less than documented BMI ( p < 0.0001). Self-reported GWG was 3.01 kg greater than documented GWG ( p < 0.0001). Ninety-eight percent of normal weight correctly classified pregravid BMI in contrast to 86% of obese ( p < 0.005) and 73% of overweight ( p < 0.001). Conclusions: Overweight and obese women underestimated self-reported pre-pregnancy weight & overestimated GWG, thereby mistakenly categorizing IOM guidelines. [ABSTRACT FROM AUTHOR]

The article presents a study which examines the effects of 17αhydroxyprogesterone caproate treatment on maternal glucose testing and gestational diabetes mellitus (GDM) within body mass index (BMI) categories. The main outcomes of the study were an abnormal 1-hour 50-gram (g) glucose screen and GDM. The results demonstrate that those women receiving weekly intramuscular 17αhydroxyprogesterone caproate have abnormal glucose testing and GDM.

A vital mission of the Society for Maternal-Fetal Medicine is to provide independent, objective, scientifically based information and recommendations for providers, patients, and payors of high-risk pregnancy care. To ensure that these recommendations are free from bias, special interest, or the perception of either, a publicly transparent process for disclosing relevant financial and nonfinancial interests (disclosures of interest) and management of potential conflicts of interest are essential. Educational and research presentations also require proper disclosure to allow attendees to properly assess information presented at the Society for Maternal-Fetal Medicine events. The Society for Maternal-Fetal Medicine established a task force to review the current Society for Maternal-Fetal Medicine policies and procedures as they pertain to disclosure of interest and conflict of interest. To establish current best practices in disclosure of interest and conflict of interest definitions, reporting, and conflict of interest mitigation, members of the task force reviewed external literature, including policies of other medical organizations. The Society for Maternal-Fetal Medicine is committed to a continuous process of improvement in the approach to these issues and will revise this policy as indicated. [ABSTRACT FROM AUTHOR]